multiple-sclerosis

Documents about multiple-sclerosis

• Medication trajectories among persons with multiple sclerosis in a Quebec birth cohort#137506HAL (France)
• Pathology of the spinal cord in progressive multiple sclerosis (primary progressive vs secondary progressive)#649237University of Nottingham Repository
• Causal effects of multiple sclerosis therapies in left-truncated registry data#684682Europe PMC
• Study Protocol of Online DBT-Mindfulness Intervention in Multiple Sclerosis#812104ClinicalTrials.gov
• Interoception and Sense of Movement in the Patient With Multiple Sclerosis#824903ClinicalTrials.gov
• Methylphenidate as Treatment Option of Fatigue in Multiple Sclerosis#830311ClinicalTrials.gov
• Study of Evobrutinib in Participants With RMS#837553ClinicalTrials.gov
• Validity and Reliability of Timed Up and Go Test in Dual-Task Conditions for Multiple Sclerosis Patients#842651ClinicalTrials.gov
• Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis#845584ClinicalTrials.gov
• Rehabilitation in Multiple Sclerosis: Influence of Exercise on Development of Insulin Resistance, Muscle Power and Aerobic Capacity#846772ClinicalTrials.gov
• Immune Regulation in Multiple Sclerosis: The Effect of Glatiramer Acetate on MicroRNA Expression in Antigen-Presenting Cells#847234ClinicalTrials.gov
• Minocycline in Clinically Isolated Syndromes (CIS)#849394ClinicalTrials.gov
• Efficacy of COVID-19 Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication#849531ClinicalTrials.gov
• Effects of GE-O System on Gait Impairments in Multiple Sclerosis Subjects#856067ClinicalTrials.gov
• Incidence, and Survival Medical Expenditure of Patients With Multiple Sclerosis#866962ClinicalTrials.gov
• Immersive Virtual Reality and Exercise Programs in Multiple Sclerosis: ExeRVIEM III#870319ClinicalTrials.gov
• Study of Brain Activations and Physiological Responses Using NeuroBiofeedback in Patients With Multiple Sclerosis#872459ClinicalTrials.gov
• The Effect of Dual Task On Upper Extremity Functions In Multiple Sclerosis Patients#884118ClinicalTrials.gov
• Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis#887199ClinicalTrials.gov
• Exploratory Pilot Study on the Prolonged Use of the ABLE Exoskeleton in Multiple Sclerosis#888992ClinicalTrials.gov
• Immunoregulatory Effect of Microparticle Delivered STING Agonist in the Control of Experimental Autoimmune Encephalomyelitis (EAE) and Multiple Sclerosis (MS)#890934ClinicalTrials.gov
• A Study to Evaluate the Real-world Experience and Satisfaction Associated With Ofatumumab#898030ClinicalTrials.gov
• Treatment of Multiple Sclerosis With Copaxone and Albuterol#911448ClinicalTrials.gov
• A Phase IIa Study of NT-KO-003 for Multiple Sclerosis#912877ClinicalTrials.gov
• Using Optical Coherence Tomography to Capture Retinal Microvascular Changes Associated With Multiple Sclerosis#914269ClinicalTrials.gov
• Effects of Head and Neck Cooling and Heating on Fatigue in Multiple Sclerosis and Healthy Men#966603ClinicalTrials.gov
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)#810834ClinicalTrials.gov
• BEYOND Pilot Study#850037ClinicalTrials.gov
• Impaired suppressive effect of FoxP3 regulatory T cells on B cells in multiple sclerosis#212949Europe PMC
• Mesenchymal stromal cells for progressive multiple sclerosis: current evidence and translational challenges#342176HAL (France)
• Inpatient care for people with multiple sclerosis - a secondary data analysis in Germany between 2019 and 2024#478609Europe PMC
• Function Magnetic Resonance Imaging to Assess Two Therapeutic Strategies in Multiple Sclerosis (NeuroRehEM).#803794ClinicalTrials.gov
• Respiratory Function and Walking Capacity in Multiple Sclerosis#803874ClinicalTrials.gov
• A Clinical Study to Evaluate the Safety and Efficacy of GT802 Injection in the Treatment of Relapsing/Refractory Multiple Sclerosis#806063ClinicalTrials.gov
• Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis#844116ClinicalTrials.gov
• 3D OPTIMIZED WMN MPRAGE Increased Detection of Focal Spinal Cord Lesion in Multiple Sclerosis (WHINUME)#846777ClinicalTrials.gov
• Effect of Need to Void on Gait Speed in Multiple Sclerosis#847370ClinicalTrials.gov
• Lung Volume Recruitment for Lung Function and Cough Impairment in Multiple Sclerosis#849231ClinicalTrials.gov
• EARLY IFNb-1a and Atorvastatin Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis#852286ClinicalTrials.gov
• Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis#877494ClinicalTrials.gov
• Virtual Reality in the Treatment of Pelvic Floor Dysfunction in Women With Multiple Sclerosis#883138ClinicalTrials.gov
• Study to Investigate Vagus Nerve Stimulation Paired With Motor Task for Remyelination and Functional Recovery#885032ClinicalTrials.gov
• Epley Manoeuvre in Participants With Multiple Sclerosis Diagnosed From Benign Paroxysmal Positional Vertigo#893121ClinicalTrials.gov
• Feasibility Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple Sclerosis#904654ClinicalTrials.gov
• Chronic Fatigue in Multiple Sclerosis: MS Copilot Boost Solution Compared to Standard Care#906067ClinicalTrials.gov
• Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)#909458ClinicalTrials.gov
• Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis#912578ClinicalTrials.gov
• The Mediating Role of Balance in the Relationship Between Fatigue and Fear of Falling in Individuals With Multiple Sclerosis#912799ClinicalTrials.gov
• Atorvastatin 40 mg in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Interferon-Beta-1b#966256ClinicalTrials.gov
• The constrained brain in multiple sclerosis: Cognitive impairment is related to network-specific coupling of structural and functional connectivity#317442HAL (France)